121 related articles for article (PubMed ID: 26875576)
1. [A comparison of efficacy and safety of linezolid versus vancomycin for the treatment of infections in patients after allogeneic hematopoietic stem cell transplantation].
Tian J; Xu Z; Liu D; Huang X; Liu K; Chen H; Chen Y; Chen Y; Zhang X; Han W; Zhang Y; Wang F; Wang Y; Yan C; Xu L
Zhonghua Nei Ke Za Zhi; 2016 Feb; 55(2):97-101. PubMed ID: 26875576
[TBL] [Abstract][Full Text] [Related]
2. Empiric use of linezolid in febrile hematology and hematopoietic stem cell transplantation patients colonized with vancomycin-resistant Enterococcus spp.
Lisboa LF; Miranda BG; Vieira MB; Dulley FL; Fonseca GG; Guimarães T; Levin AS; Shikanai-Yasuda MA; Costa SF
Int J Infect Dis; 2015 Apr; 33():171-6. PubMed ID: 25660090
[TBL] [Abstract][Full Text] [Related]
3. Comparative study on safety of linezolid and vancomycin in the treatment of infants and neonates for Gram-positive bacterial infections.
Shibata Y; Yamagishi Y; Mikamo H; Kato H; Nishiyama N; Asai N; Koizumi Y; Matsuura K; Suematsu H; Hagihara M
J Infect Chemother; 2018 Sep; 24(9):695-701. PubMed ID: 29807867
[TBL] [Abstract][Full Text] [Related]
4. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
6. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
7. Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens.
Jantausch BA; Deville J; Adler S; Morfin MR; Lopez P; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S164-71. PubMed ID: 14520142
[TBL] [Abstract][Full Text] [Related]
8. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
9. Linezolid more efficacious than vancomycin to eradicate infecting organism in critically ill patients with Gram-positive infections.
Sirvent JM; Piñeiro L; de la Torre M; Motjé M; de Batlle J; Bonet A
Rev Esp Quimioter; 2010 Mar; 23(1):27-35. PubMed ID: 20232021
[TBL] [Abstract][Full Text] [Related]
10. Linezolid for the treatment of complicated skin and skin structure infections in children.
Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
[TBL] [Abstract][Full Text] [Related]
11. Hematologic safety profile of linezolid in the early periengraftment period after allogeneic stem cell transplantation.
Cohen N; Mihu CN; Seo SK; Chung D; Chou J; Heller G; Papanicolaou GA
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1337-41. PubMed ID: 19747643
[TBL] [Abstract][Full Text] [Related]
12. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
[TBL] [Abstract][Full Text] [Related]
13. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
14. [Clinical efficacy and safety of vancomycin compared with linezolid for the treatment of neonatal gram-positive bacterial sepsis].
Tang L; Fang J; Wang SN; Weng XH; Li JJ; Shang EN
Zhonghua Er Ke Za Zhi; 2016 Sep; 54(9):686-91. PubMed ID: 27596084
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective analysis of the Gram-positive bacteria-infected cases in the Department of Hematology].
Jing Y; Bo J; Zhao Y; Li HH; Wang SH; Huang WR; Wang QS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1291-5. PubMed ID: 24156452
[TBL] [Abstract][Full Text] [Related]
16. Hematologic effects of linezolid in young children.
Meissner HC; Townsend T; Wenman W; Kaplan SL; Morfin MR; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S186-92. PubMed ID: 14520145
[TBL] [Abstract][Full Text] [Related]
17. Review of meta-analyses of vancomycin compared with new treatments for Gram-positive skin and soft-tissue infections: Are we any clearer?
Tsoulas C; Nathwani D
Int J Antimicrob Agents; 2015 Jul; 46(1):1-7. PubMed ID: 25982913
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.
Kingsley J; Mehra P; Lawrence LE; Henry E; Duffy E; Cammarata SK; Pullman J
J Antimicrob Chemother; 2016 Mar; 71(3):821-9. PubMed ID: 26679243
[TBL] [Abstract][Full Text] [Related]
19. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
Wilcox M; Nathwani D; Dryden M
J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
[TBL] [Abstract][Full Text] [Related]
20. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin.
Kollef MH; Rello J; Cammarata SK; Croos-Dabrera RV; Wunderink RG
Intensive Care Med; 2004 Mar; 30(3):388-94. PubMed ID: 14714107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
